Are we already seeing a slowdown?

GLP-1 medication and the meals {industry} abstract

• GLP-1 medication reshape meals {industry} deal with weight reduction
• Unwanted effects and beauty considerations are tempering enthusiasm amongst some customers
• Entry expands through capsule codecs patent expiry and rising multi-agonists
• Family consuming and buying shifts might amplify impacts past customers
• Decrease calorie consumption threatens quantity gross sales regardless of more healthy class alternatives

GLP-1 medication have dominated the meals and beverage dialog for the previous twelve months.

They’ve reignited an industry-wide fixation on weight reduction as physique positivity wanes, pushed waves of latest product growth, and confirmed an enormous crowd draw at shows and panel discussions on the topic.

However has the {industry} jumped on the GLP-1 bandwagon too quickly?

With well being and beauty considerations rising, there are indicators the development is already shedding its attraction.

Is the tide turning on GLP-1s?

Mounting stories of unwanted side effects – from gastrointestinal misery to extra critical dangers comparable to blindness and acute pancreatitis – are already dulling the shine of the so‑referred to as marvel medication.

Added to this, the time period “Ozempic face” is turning into more and more recognised as a manner of describing both puffiness from the consequences of the medication or facial hollowness – sagging pores and skin and elevated wrinkles – from fast fats loss.

However whereas this may be turning some customers away from GLP-1s their attraction continues to develop, significantly amongst first timers, as they turn into more and more accessible.

“The primary capsule codecs are simply now hitting the market,” says Matthew Barry, international perception supervisor for meals at Euromonitor Worldwide. “Semaglutide patent protections are expiring in a lot of the world, and the stronger multi-agonists are more likely to turn into commercially accessible comparatively quickly.”

In truth, removed from declining, Barry argues we’re “solely in the beginning of the GLP-1 revolution”.

Though value stays a significant barrier to wider adoption and except they “fall considerably in value” they’ll fail to succeed in full market penetration. “The best threat to enthusiasm is that if no vital progress is made in decreasing prices and growing protection charges.”

He provides {that a} “vital variety of folks” nonetheless count on “devastating long-term facet impact to be found”, regardless of little proof to assist such considerations. “That perception is having at the least a minor impact on uptake.”

Although he’s fast to level out that what is thought in regards to the well being implications of GLP‑1s is predicated solely on medication already in circulation. “Tablets and multi-agonists might be totally different in how vital they’re of their unwanted side effects.”

GLP-1 family impression

In addition to wanting on the behaviours of latest and present GLP-1 customers, meals and beverage producers are additionally focusing their attentions on the folks they dwell with, in what’s now being termed the “family impact”.

This impact is notoriously exhausting to totally perceive. And that, says Barry, is what makes it so compelling.

Many of the analysis on GLP‑1s stays tightly targeted on the person person, but consuming isn’t a person act. Meals buying, meal planning and consumption selections are made on the family stage. When one particular person begins consuming much less, buying in another way, or avoiding sure meals altogether, these modifications ripple outward to companions, youngsters and different family members.

Solely a handful of research even try to seize these dynamics, and in a lot of the evaluation to this point the family impact is successfully invisible. That blind spot issues. Ignoring the oblique affect GLP‑1 customers have on the diets and shopping for habits of these round them dangers materially understating the medication’ real-world impression. For the meals {industry} specifically, this implies demand shifts could also be broader, sooner and extra structural than particular person utilization charges alone would counsel.

Meals and beverage gross sales decline

Whereas {industry} consideration has been focussed closely on the impression of GLP-1 medication, there’s been a reluctance to confess the impression they might have on quantity gross sales.

There’ll, says Barry, be positive aspects in more healthy classes however there is no such thing as a manner that fully compensates for declines elsewhere.

“If folks eat much less, meals firms will promote much less and there’s no escaping that.”

What’s extra, this is only one of many quantity headwinds the {industry} is going through, with excessive costs, weak client confidence, and a troublesome demographic outlook all weighing on demand.

The place does this go away the {industry}?

For meals and beverage firms, GLP‑1s symbolize each a real development alternative and a structural menace.

There’s clear potential in merchandise tailor-made to smaller appetites, increased protein wants, improved nutrient density and digestive consolation. Manufacturers that may credibly ship satiety, reassurance and useful advantages might discover new relevance not solely with GLP‑1 customers, however with total households adjusting to modified consuming patterns.

But the dangers are simply as vital. If calorie consumption falls meaningfully at scale, volume-led development fashions start to creak.

Reformulation alone received’t resolve that downside, and never each class can commerce down on portion measurement whereas buying and selling up on worth.

Over‑indexing on GLP‑1‑particular innovation additionally carries hazard if client enthusiasm softens, unwanted side effects achieve prominence or entry stalls on value and reimbursement. The {industry} might find yourself chasing a transferring goal – or worse, overbuilding round a development whose full form remains to be rising.

Crucially, there may be nonetheless much more that the {industry} doesn’t know than it does. Lengthy‑time period utilization patterns stay unclear. Will folks keep on GLP‑1s indefinitely, cycle on and off, or abandon them altogether? Will drugs and multi‑agonists change adherence, outcomes or facet‑impact profiles in ways in which materially alter consuming behaviour? How will youngsters in “GLP‑1 households” be affected over time? And the way will regulators, insurers and well being methods reply as utilization expands?

What is evident is that GLP‑1s are forcing the meals and beverage {industry} to confront some uncomfortable questions it has lengthy skirted round – what occurs when much less meals actually is eaten, and when well being outcomes, not consumption, turn into a extra express organising precept of the market.